非小细胞肺癌软脑膜转移患者接受免疫检查点抑制剂治疗的临床结局
本研究在广东省肺癌研究所筛选2015年1月至2020年3月诊断软脑膜转移(LM)的255例非小细胞肺癌(NSCLC)患者,最终纳入32例在LM诊断后接受免疫检查点抑制剂(ICI)治疗者并结合文献复习。结果显示部分患者神经系统症状得到控制并可出现颅内及颅外缓解,单药与联合亚组的中位无进展生存期(PFS)分别为2.1个月与3.0个月,中位总生存期(OS)分别为4.0个月与5.4个月,较好的ECOG-PS评分与PFS延长相关。
要点
- LM后接受ICI治疗者可见神经系统症状控制及颅内、颅外肿瘤缓解。
- 单药与联合治疗亚组生存无差异,较好ECOG-PS与PFS延长相关。
- 3例PFS超过20个月者均为单药、ICI前接受过颅脑放疗且ICI为二线治疗。
核心结论
- NSCLC合并LM患者可能从单药或联合其他治疗的ICI中获益,尤其是ECOG-PS评分较好者,仍需进一步研究。
研究设计与样本
- 在广东省肺癌研究所筛选2015年1月至2020年3月诊断LM的255例NSCLC患者,并纳入文献报道病例,最终32例在LM诊断后接受ICI治疗,中位年龄55岁。
主要发现
- 62.5%的患者神经系统症状得到控制。
- 2例颅内和颅外均完全缓解,1例颅内和颅外均部分缓解(PR),1例颅内PR且全身PR,1例中枢神经系统PR而未报告颅外缓解。
- 单药亚组中位PFS为2.1个月(95%CI:1.4-2.9个月),中位OS为4.0个月(95%CI:0.1-13.3个月)。
- 联合亚组中位PFS为3.0个月(95%CI:1.1-4.9个月),中位OS为5.4个月(95%CI:0.5-10.3个月)。
- 3例PFS超过20个月者均为ICI单药、ICI前接受颅脑放疗、ICI作为二线治疗,其中2例为EGFR/ALK野生型。
关键数值与推荐
- 可靶向基因在全部患者中检出率为37.5%。
- ICI方案包括纳武利尤单抗(n = 21)、帕博利珠单抗(n = 9)和阿替利珠单抗(n = 2)。
临床怎么用
- 对ECOG-PS较好的NSCLC软脑膜转移患者,可考虑ICI单药或联合治疗,并在ICI前评估颅脑放疗等既往治疗背景。
局限性
- 本研究为单中心回顾性资料并结合文献病例,样本量有限,结论需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Leptomeningeal metastases (LM) occur in up to 5% of non-small cell lung cancer (NSCLC) patients and often develop after previous systemic treatments. In this article, we explored whether immune checkpoint inhibitors (ICIs) enhanced the dismal survival of patients with LM. MATERIALS AND METHODS: Data on NSCLC patients with LM prescribed ICIs were collected at the Guangdong Lung Cancer Institute. Furthermore, relevant literature was reviewed. RESULTS: A total of 255 NSCLC patients diagnosed with LM were screened from January 2015 to March 2020 at our institute. Cases reported by literature were also included. Finally, 32 NSCLC patients received ICIs after LM diagnosis; their median age was 55 years. Druggable genes were detected in 37.5% of all patients. The ICI regimens included nivolumab (n = 21), pembrolizumab (n = 9), and atezolizumab (n = 2). Ultimately, 62.5% of patients evidenced neurological symptom controlled. Two patients exhibited both intracranial and extracranial complete tumour response; one patient showed both intracranial and extracranial partial response (PR), one patient indicated intracranial PR and a systemic PR, and one patient showed central nervous system PR without extracranial response reported. The median progression-free survival (PFS) in the single-agent subgroup was 2.1 months (95% confidence interval [CI]: 1.4-2.9 months), and the median overall survival (OS) was 4.0 months (95% CI: 0.1-13.3 months). In the combined subgroup, the median PFS and OS were 3.0 months (95% CI: 1.1-4.9 months) and 5.4 months (95% CI: 0.5-10.3 months), respectively. Three patients exhibited remarkable PFS of over 20 months: all patients had ICI single agent, received cranial radiotherapy before ICI prescription, and took ICIs as second-line therapy, and two patients were EGFR/ALK wild type. Multivariate analysis showed that a better Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score was associated with prolonged PFS (P = 0.04). No difference in survival was seen between monotherapy and combination therapy groups. CONCLUSION: NSCLC patients with LM may benefit from ICIs of both monotherapy and combination with other therapies, especially those with good ECOG-PS scores. Further work in this regard is required.
引用
- Zheng MM, Tu HY, Yang JJ, et al. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. Eur J Cancer. 2021. PMID: 33882375. doi:10.1016/j.ejca.2021.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。